← Back to News & Updates
Cost Implications of Orphan Drugs for Organizations
Nov 29, 2016
The prices charged for many orphan drugs are extremely high - up to $500,000 per-year per-patient, with over $100,000 per year average costs. Orphan drugs are aimed at extremely rare diseases; defined as afflicting fewer than 200,000 patients in the U.S. Out of approximately 7,000 known rare diseases, 95% still have no approved therapies. Collectively, about 30 million Americans are impacted by a rare disease.
View the full report to look at what this means to the organizations that are primarily responsible for paying for these crucial, but very expensive drugs: insurance companies and self-insured employer groups often assisted by Pharmacy Benefit Managers.
For questions, please contact a member of your b&p Sales Team - 888.722.3373.